Abstract
IL-5 is an important cytokine for priming and survival of mature eosinophils and for proliferation and maturation of their progenitors. Hence, IL-5(Rα) targeting will be increasingly used in diseases where eosinophils are the key immune effector cells such as eosinophilic asthma (EA), hypereosinophilic syndrome (HES), eosinophilic esophagitis (EE), and eosinophilic granulomatosis with polyangiitis (EGPA). Therefore, several neutralizing monoclonal antibodies directed against IL-5 (mepolizumab and reslizumab) and its receptor IL-5Rα (benralizumab) have found or will find their way to the clinic. While the clinical effect of these drugs has been extensively investigated and reviewed, the understanding of the underlying immunological and hematological mechanisms remains less clear. This review will discuss the translational outcomes of treatment with these monoclonal antibodies in humans to shed light on the mechanisms underlying the main immunological and hematological findings from these clinical trials in humans.
| Original language | English |
|---|---|
| Pages (from-to) | 1979-1988 |
| Number of pages | 10 |
| Journal | Allergy |
| Volume | 73 |
| Issue number | 10 |
| Early online date | 3 Apr 2018 |
| DOIs | |
| Publication status | Published - Oct 2018 |
Keywords
- Journal Article
- Review
- asthma therapy
- IL-5
- eosinophils
- asthma
- anti-IL-5
- Humans
- Antibodies, Monoclonal/therapeutic use
- Receptors, Interleukin-5/immunology
- Translational Medical Research/trends
- Eosinophils/immunology
- Interleukin-5/immunology